JOHNSON & JOHNSON (JNJ.DE) Fundamental Analysis & Valuation

FRA:JNJ • US4781601046

206.25 EUR
-4.9 (-2.32%)
Last: Mar 5, 2026, 05:25 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership

This JNJ.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

6

Overall JNJ gets a fundamental rating of 6 out of 10. We evaluated JNJ against 49 industry peers in the Pharmaceuticals industry. JNJ has an excellent profitability rating, but there are some minor concerns on its financial health. JNJ is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

8

1. JNJ.DE Profitability Analysis

1.1 Basic Checks

  • JNJ had positive earnings in the past year.
  • In the past year JNJ had a positive cash flow from operations.
  • Each year in the past 5 years JNJ has been profitable.
  • Each year in the past 5 years JNJ had a positive operating cash flow.
JNJ.DE Yearly Net Income VS EBIT VS OCF VS FCFJNJ.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10B 20B 30B

1.2 Ratios

  • With an excellent Return On Assets value of 13.46%, JNJ belongs to the best of the industry, outperforming 85.71% of the companies in the same industry.
  • The Return On Equity of JNJ (32.87%) is better than 81.63% of its industry peers.
  • With a decent Return On Invested Capital value of 14.37%, JNJ is doing good in the industry, outperforming 73.47% of the companies in the same industry.
  • JNJ had an Average Return On Invested Capital over the past 3 years of 16.34%. This is above the industry average of 13.98%.
Industry RankSector Rank
ROA 13.46%
ROE 32.87%
ROIC 14.37%
ROA(3y)14.08%
ROA(5y)12.66%
ROE(3y)34.55%
ROE(5y)31.04%
ROIC(3y)16.34%
ROIC(5y)15%
JNJ.DE Yearly ROA, ROE, ROICJNJ.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10 20 30 40 50

1.3 Margins

  • JNJ has a better Profit Margin (28.46%) than 89.80% of its industry peers.
  • In the last couple of years the Profit Margin of JNJ has grown nicely.
  • JNJ has a better Operating Margin (27.78%) than 75.51% of its industry peers.
  • In the last couple of years the Operating Margin of JNJ has grown nicely.
  • Looking at the Gross Margin, with a value of 67.92%, JNJ is in line with its industry, outperforming 48.98% of the companies in the same industry.
  • JNJ's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 27.78%
PM (TTM) 28.46%
GM 67.92%
OM growth 3Y6.15%
OM growth 5Y6.99%
PM growth 3Y8.26%
PM growth 5Y9.82%
GM growth 3Y-0.67%
GM growth 5Y0.65%
JNJ.DE Yearly Profit, Operating, Gross MarginsJNJ.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. JNJ.DE Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so JNJ is still creating some value.
  • JNJ has about the same amout of shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, JNJ has less shares outstanding
  • JNJ has a worse debt/assets ratio than last year.
JNJ.DE Yearly Shares OutstandingJNJ.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B 2.5B
JNJ.DE Yearly Total Debt VS Total AssetsJNJ.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50B 100B 150B

2.2 Solvency

  • An Altman-Z score of 5.12 indicates that JNJ is not in any danger for bankruptcy at the moment.
  • JNJ's Altman-Z score of 5.12 is fine compared to the rest of the industry. JNJ outperforms 75.51% of its industry peers.
  • The Debt to FCF ratio of JNJ is 2.43, which is a good value as it means it would take JNJ, 2.43 years of fcf income to pay off all of its debts.
  • The Debt to FCF ratio of JNJ (2.43) is better than 79.59% of its industry peers.
  • A Debt/Equity ratio of 0.56 indicates that JNJ is somewhat dependend on debt financing.
  • JNJ's Debt to Equity ratio of 0.56 is in line compared to the rest of the industry. JNJ outperforms 59.18% of its industry peers.
  • Although JNJ does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
Industry RankSector Rank
Debt/Equity 0.56
Debt/FCF 2.43
Altman-Z 5.12
ROIC/WACC1.54
WACC9.36%
JNJ.DE Yearly LT Debt VS Equity VS FCFJNJ.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20B 40B 60B 80B

2.3 Liquidity

  • JNJ has a Current Ratio of 1.03. This is a normal value and indicates that JNJ is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 1.03, JNJ is doing worse than 77.55% of the companies in the same industry.
  • JNJ has a Quick Ratio of 1.03. This is a bad value and indicates that JNJ is not financially healthy enough and could expect problems in meeting its short term obligations.
  • The Quick ratio of JNJ (0.77) is worse than 73.47% of its industry peers.
  • The current and quick ratio evaluation for JNJ is rather negative, while it does have excellent solvency and profitability. These ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
Industry RankSector Rank
Current Ratio 1.03
Quick Ratio 0.77
JNJ.DE Yearly Current Assets VS Current LiabilitesJNJ.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20B 40B 60B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. JNJ.DE Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an nice 8.11% over the past year.
  • The Earnings Per Share has been growing slightly by 6.11% on average over the past years.
  • The Revenue has been growing slightly by 6.05% in the past year.
  • The Revenue has been growing slightly by 2.67% on average over the past years.
EPS 1Y (TTM)8.11%
EPS 3Y2.06%
EPS 5Y6.11%
EPS Q2Q%20.59%
Revenue 1Y (TTM)6.05%
Revenue growth 3Y5.6%
Revenue growth 5Y2.67%
Sales Q2Q%9.08%

3.2 Future

  • The Earnings Per Share is expected to grow by 8.75% on average over the next years. This is quite good.
  • JNJ is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 6.02% yearly.
EPS Next Y7.88%
EPS Next 2Y8.2%
EPS Next 3Y8.39%
EPS Next 5Y8.75%
Revenue Next Year7.21%
Revenue Next 2Y6.4%
Revenue Next 3Y6.15%
Revenue Next 5Y6.02%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
JNJ.DE Yearly Revenue VS EstimatesJNJ.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 20B 40B 60B 80B 100B
JNJ.DE Yearly EPS VS EstimatesJNJ.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5 10 15

More info and screens

Find the best growth stocksShow best growing peers

3

4. JNJ.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 22.25, the valuation of JNJ can be described as rather expensive.
  • The rest of the industry has a similar Price/Earnings ratio as JNJ.
  • JNJ is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 27.03, which is the current average of the S&P500 Index.
  • JNJ is valuated rather expensively with a Price/Forward Earnings ratio of 20.62.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of JNJ is on the same level as its industry peers.
  • JNJ is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 25.11, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 22.25
Fwd PE 20.62
JNJ.DE Price Earnings VS Forward Price EarningsJNJ.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • JNJ's Enterprise Value to EBITDA ratio is in line with the industry average.
  • JNJ's Price/Free Cash Flow ratio is in line with the industry average.
Industry RankSector Rank
P/FCF 29.39
EV/EBITDA 17.92
JNJ.DE Per share dataJNJ.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • The excellent profitability rating of JNJ may justify a higher PE ratio.
PEG (NY)2.83
PEG (5Y)3.64
EPS Next 2Y8.2%
EPS Next 3Y8.39%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

5

5. JNJ.DE Dividend Analysis

5.1 Amount

  • With a Yearly Dividend Yield of 2.14%, JNJ has a reasonable but not impressive dividend return.
  • JNJ's Dividend Yield is a higher than the industry average which is at 1.84.
  • Compared to an average S&P500 Dividend Yield of 1.82, JNJ has a dividend comparable with the average S&P500 company.
Industry RankSector Rank
Dividend Yield 2.14%

5.2 History

  • On average, the dividend of JNJ grows each year by 7.68%, which is quite nice.
Dividend Growth(5Y)7.68%
Div Incr Years6
Div Non Decr Years6
JNJ.DE Yearly Dividends per shareJNJ.DE Yearly Dividends per shareYearly Dividends per share 2018 2019 2020 2021 2022 2023 2024 2025 2026 1 2 3 4 5

5.3 Sustainability

  • 46.19% of the earnings are spent on dividend by JNJ. This is a bit on the high side, but may be sustainable.
  • The dividend of JNJ is growing around the same rate as the earnings are growing. If this keeps up the dividend growth is sustainable.
DP46.19%
EPS Next 2Y8.2%
EPS Next 3Y8.39%
JNJ.DE Yearly Income VS Free CF VS DividendJNJ.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10B 20B 30B
JNJ.DE Dividend Payout.JNJ.DE Dividend Payout, showing the Payout Ratio.JNJ.DE Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

JNJ.DE Fundamentals: All Metrics, Ratios and Statistics

JOHNSON & JOHNSON

FRA:JNJ (3/5/2026, 5:25:39 PM)

206.25

-4.9 (-2.32%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)01-21
Earnings (Next)04-14
Inst Owners75.09%
Inst Owner ChangeN/A
Ins Owners0.03%
Ins Owner ChangeN/A
Market Cap496.92B
Revenue(TTM)94.19B
Net Income(TTM)26.80B
Analysts75.63
Price Target200.81 (-2.64%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 2.14%
Yearly Dividend4.36
Dividend Growth(5Y)7.68%
DP46.19%
Div Incr Years6
Div Non Decr Years6
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.21%
Min EPS beat(2)-0.13%
Max EPS beat(2)0.55%
EPS beat(4)3
Avg EPS beat(4)2.17%
Min EPS beat(4)-0.13%
Max EPS beat(4)5.96%
EPS beat(8)7
Avg EPS beat(8)2.84%
EPS beat(12)10
Avg EPS beat(12)3.23%
EPS beat(16)14
Avg EPS beat(16)3.09%
Revenue beat(2)2
Avg Revenue beat(2)0.35%
Min Revenue beat(2)0.03%
Max Revenue beat(2)0.67%
Revenue beat(4)4
Avg Revenue beat(4)1.04%
Min Revenue beat(4)0.03%
Max Revenue beat(4)2.92%
Revenue beat(8)5
Avg Revenue beat(8)0.32%
Revenue beat(12)8
Avg Revenue beat(12)-0.5%
Revenue beat(16)8
Avg Revenue beat(16)-4.44%
PT rev (1m)9.87%
PT rev (3m)14.02%
EPS NQ rev (1m)0.03%
EPS NQ rev (3m)-3.15%
EPS NY rev (1m)0.79%
EPS NY rev (3m)-0.01%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2.04%
Revenue NY rev (1m)0.43%
Revenue NY rev (3m)1.84%
Valuation
Industry RankSector Rank
PE 22.25
Fwd PE 20.62
P/S 6.15
P/FCF 29.39
P/OCF 23.6
P/B 7.1
P/tB N/A
EV/EBITDA 17.92
EPS(TTM)9.27
EY4.49%
EPS(NY)10
Fwd EY4.85%
FCF(TTM)7.02
FCFY3.4%
OCF(TTM)8.74
OCFY4.24%
SpS33.56
BVpS29.05
TBVpS-6.28
PEG (NY)2.83
PEG (5Y)3.64
Graham Number77.85
Profitability
Industry RankSector Rank
ROA 13.46%
ROE 32.87%
ROCE 18.03%
ROIC 14.37%
ROICexc 16.57%
ROICexgc 67.45%
OM 27.78%
PM (TTM) 28.46%
GM 67.92%
FCFM 20.91%
ROA(3y)14.08%
ROA(5y)12.66%
ROE(3y)34.55%
ROE(5y)31.04%
ROIC(3y)16.34%
ROIC(5y)15%
ROICexc(3y)19.6%
ROICexc(5y)18.23%
ROICexgc(3y)74.51%
ROICexgc(5y)73.44%
ROCE(3y)20.24%
ROCE(5y)18.7%
ROICexgc growth 3Y3.9%
ROICexgc growth 5Y-2.01%
ROICexc growth 3Y8.52%
ROICexc growth 5Y5.62%
OM growth 3Y6.15%
OM growth 5Y6.99%
PM growth 3Y8.26%
PM growth 5Y9.82%
GM growth 3Y-0.67%
GM growth 5Y0.65%
F-Score4
Asset Turnover0.47
Health
Industry RankSector Rank
Debt/Equity 0.56
Debt/FCF 2.43
Debt/EBITDA 1.36
Cap/Depr 64.4%
Cap/Sales 5.13%
Interest Coverage 6.81
Cash Conversion 72.86%
Profit Quality 73.49%
Current Ratio 1.03
Quick Ratio 0.77
Altman-Z 5.12
F-Score4
WACC9.36%
ROIC/WACC1.54
Cap/Depr(3y)61.79%
Cap/Depr(5y)58.46%
Cap/Sales(3y)5.15%
Cap/Sales(5y)5.02%
Profit Quality(3y)88.82%
Profit Quality(5y)91.38%
High Growth Momentum
Growth
EPS 1Y (TTM)8.11%
EPS 3Y2.06%
EPS 5Y6.11%
EPS Q2Q%20.59%
EPS Next Y7.88%
EPS Next 2Y8.2%
EPS Next 3Y8.39%
EPS Next 5Y8.75%
Revenue 1Y (TTM)6.05%
Revenue growth 3Y5.6%
Revenue growth 5Y2.67%
Sales Q2Q%9.08%
Revenue Next Year7.21%
Revenue Next 2Y6.4%
Revenue Next 3Y6.15%
Revenue Next 5Y6.02%
EBIT growth 1Y12.82%
EBIT growth 3Y12.1%
EBIT growth 5Y9.84%
EBIT Next Year23.18%
EBIT Next 3Y11.51%
EBIT Next 5Y8.55%
FCF growth 1Y-0.73%
FCF growth 3Y4.65%
FCF growth 5Y-0.49%
OCF growth 1Y1.09%
OCF growth 3Y4.99%
OCF growth 5Y0.83%

JOHNSON & JOHNSON / JNJ.DE FAQ

Can you provide the ChartMill fundamental rating for JOHNSON & JOHNSON?

ChartMill assigns a fundamental rating of 6 / 10 to JNJ.DE.


What is the valuation status of JOHNSON & JOHNSON (JNJ.DE) stock?

ChartMill assigns a valuation rating of 3 / 10 to JOHNSON & JOHNSON (JNJ.DE). This can be considered as Overvalued.


What is the profitability of JNJ stock?

JOHNSON & JOHNSON (JNJ.DE) has a profitability rating of 8 / 10.


Can you provide the financial health for JNJ stock?

The financial health rating of JOHNSON & JOHNSON (JNJ.DE) is 6 / 10.


Is the dividend of JOHNSON & JOHNSON sustainable?

The dividend rating of JOHNSON & JOHNSON (JNJ.DE) is 5 / 10 and the dividend payout ratio is 46.19%.